Richter transformation (RT) refers to the occurrence of an aggressive and treatment-resistant lymphoma that arises from the progression of chronic lymphocytic leukemia (CLL) and is associated with a poor prognosis. Disruptive mutations in the BCL6 co-repressor (Bcor) gene are found in up to 2% of CLL cases and often occur alongside Notch1 mutations, a common molecular alteration linked to RT. This co-occurrence points to a possible cooperative role in driving disease progression.

Researchers from Aarhus University and Synuca Therapeutics recently presented a novel drug-like small-molecule inhibitor of sarco/endoplasmic reticulum calcium ATPase (SERCA), SYN-4569, with superior pharmacological properties and evaluated its efficacy in vitro and in vivo. SYN-4569 is an orally available compound with good potency, pharmacokinetics and brain-penetrant properties.

CC chemokine receptor 6 (CCR6) is a G-protein coupled receptor involved in guiding immune cells through the body and the hallmark receptor for T helper 17 (Th17) cells, and is also expressed in other immune cell populations, such as B cells and innate lymphoid cells, among others.

Syntis Bio Inc. has presented preclinical data regarding their antiobesity compound SYNT-101 in the preclinical setting.

1st Biotherapeutics Inc. and Ligachem Biosciences Inc. have entered into a strategic partnership and licensing option agreement.